Literature DB >> 17009860

Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.

Ben J Boyd1, Lisa M Kaminskas, Peter Karellas, Guy Krippner, Romina Lessene, Christopher J H Porter.   

Abstract

Cationic poly-L-lysine 3H-dendrimers with either 16 or 32 surface amine groups (BHALys [Lys]4 [3H-Lys]8 [NH2]16 and BHALys [Lys]8 [3H-Lys]16 [NH2]32, generation 3 and 4, respectively) have been synthesized and their pharmacokinetics and biodistribution investigated after intravenous administration to rats. The species in plasma with which radiolabel was associated was also investigated by size exclusion chromatography (SEC). Rapid initial removal of radiolabel from plasma was evident for both dendrimers (t(1/2) < 5 min). Approximately 1 h postdose, however, radiolabel reappeared in plasma in the form of free lysine and larger (but nondendrimer) species that coeluted with albumin by SEC. Plasma and whole blood pharmacokinetics were similar, precluding interaction with blood components as a causative factor in either the rapid removal or reappearance of radioactivity in plasma. Administration of monomeric 3H L-lysine also resulted in the appearance in plasma of a radiolabeled macromolecular species that coeluted with albumin by SEC, suggesting that biodegradation of the dendrimer to L-lysine and subsequent bioresorption may explain the pharmacokinetic profiles. Capping the Lys8 dendrimer with D-lysine to form BHALys [Lys]4 [3H-Lys]8 [D-Lys]16 [NH2]32 resulted in similar, and very rapid, initial disappearance kinetics from plasma when compared to the L-lysine capped dendrimer. Since significant extravasation of these large hydrophilic molecules seems unlikely, this most likely reflects both elimination and extensive binding to vascular surfaces. Capping with "non-natural" D-lysine also appeared to render the dendrimer essentially inert to the biodegradation process. For the L-lysine capped dendrimers, radiolabel was widely distributed throughout the major organs, with no apparent selectivity for organs of the reticuloendothelial system. In contrast, a greater proportion of the administered radiolabel was recovered in the organs of the reticuloendothelial system for the D-lysine capped system, as might be expected for a nondegrading circulating foreign colloid. To our knowledge this is the first data to demonstrate the biodegradation/bioresorption of poly-L-lysine dendrimers and has significant implications for the utility of these systems as drugs or drug delivery systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009860     DOI: 10.1021/mp060032e

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  21 in total

Review 1.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

2.  A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep.

Authors:  Gemma M Ryan; Robert J Bischof; Perenlei Enkhbaatar; Victoria M McLeod; Linda J Chan; Seth A Jones; David J Owen; Christopher J H Porter; Lisa M Kaminskas
Journal:  Pharm Res       Date:  2015-10-20       Impact factor: 4.200

3.  PD-L1- and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease.

Authors:  Ryan Galea; Hendrik J Nel; Meghna Talekar; Xiao Liu; Joshua D Ooi; Megan Huynh; Sara Hadjigol; Kate J Robson; Yi Tian Ting; Suzanne Cole; Karyn Cochlin; Shannon Hitchcock; Bijun Zeng; Suman Yekollu; Martine Boks; Natalie Goh; Helen Roberts; Jamie Rossjohn; Hugh H Reid; Ben J Boyd; Ravi Malaviya; David J Shealy; Daniel G Baker; Loui Madakamutil; A Richard Kitching; Brendan J O'Sullivan; Ranjeny Thomas
Journal:  JCI Insight       Date:  2019-09-19

4.  Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth.

Authors:  Khuloud T Al-Jamal; Wafa' T Al-Jamal; Simon Akerman; Jennifer E Podesta; Açelya Yilmazer; John A Turton; Alberto Bianco; Neil Vargesson; Chryso Kanthou; Alexander T Florence; Gillian M Tozer; Kostas Kostarelos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-11       Impact factor: 11.205

5.  Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Authors:  David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

Review 6.  Effects of nanomaterial physicochemical properties on in vivo toxicity.

Authors:  Kristin L Aillon; Yumei Xie; Nashwa El-Gendy; Cory J Berkland; M Laird Forrest
Journal:  Adv Drug Deliv Rev       Date:  2009-04-20       Impact factor: 15.470

Review 7.  Complex polyamines: unique prion disaggregating compounds.

Authors:  Surachai Supattapone; Justin R Piro; Judy R Rees
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-11       Impact factor: 4.388

8.  Evidence of oral translocation of anionic G6.5 dendrimers in mice.

Authors:  Giridhar Thiagarajan; Shraddha Sadekar; Khaled Greish; Abhijit Ray; Hamidreza Ghandehari
Journal:  Mol Pharm       Date:  2013-01-25       Impact factor: 4.939

9.  Genome-free viral capsids as carriers for positron emission tomography radiolabels.

Authors:  Jacob M Hooker; James P O'Neil; Dante W Romanini; Scott E Taylor; Matthew B Francis
Journal:  Mol Imaging Biol       Date:  2008-04-25       Impact factor: 3.488

10.  Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution.

Authors:  Qian Zhong; Olivia M Merkel; Joshua J Reineke; Sandro R P da Rocha
Journal:  Mol Pharm       Date:  2016-05-13       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.